Hester Biosciences Ltd

NSE
HESTERBIO •
BUY

1W Return

-%

1M Return

-%

6M Return

-%

1Y Return

-%

3Y Return

-%

Start SIP in Hester Biosciences Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
New 52W Low today
-5
TTM PE Ratio
High in industry
65.3
Price to Book Ratio
Above industry Median
4.2
Dividend yield 1yr %
Below industry Median
0.6
TTM PEG Ratio
PEG TTM is negative
-1.7
RSI
RSI is mid-range
44.2
MFI
MFI is mid-range
37

Hester Biosciences Ltd Key Financials

*All values are in ₹ Cr.

Hester Biosciences Ltd shareholding Pattern

Promoter
53.7%
Foreign Institutions
0.4%
Public
45.8%

Hester Biosciences Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
6
Bearish Moving Averages
10
5Day EMA
1,408.20
10Day EMA
1,412.70
12Day EMA
1,415.20
20Day EMA
1,427.00
26Day EMA
1,435.70
50Day EMA
1,465.50
100Day EMA
1,517.90
200Day EMA
1,603.70
Delivery & Volume
Resistance & Support
1,410.00
Pivot
Resistance
First Resistance
1,436
Second Resistance
1,454.85
Third Resistance
1,480.85
Support
First Support
1,391.15
Second support
1,365.15
Third Support
1,346.30
Relative Strength Index
44.17
Money Flow Index
37.02
MACD
-20.48
MACD Signal
-22.22
Average True Range
31.29
Average Directional Index
22.92
Rate of Change (21)
-7.19
Rate of Change (125)
-17.57

Hester Biosciences Ltd Company background

Founded in: 1987
Hester Biosciences Limited is one of the leading and pioneering animal healthcare companies in India. Since its incorporation in Apr 87, the Company has been engaged in the production and distribution of vaccines and health products. Headquartered in Ahmedabad, Gujarat, the Company is currently the secondlargest maker of poultry vaccines in India, having acquired strong brand equity over the years. The Company principally engages in two business verticals, namely Poultry Healthcare and Animal Healthcare. Its products are registered with several countries, and internal agencies, and have gained widespread recognition in both India and international markets. It has built a presence in several regions of Africa and in numerous nations, including Vietnam, Indonesia, Nepal, and Bangladesh. The products and services offered include over 51 vaccines and 70+ health products. In addition, it offers a vast selection of pharmaceuticals, feed supplements, and disinfectants for poultry and large animals.The Company markets and distributes veterinary and pharmaceutical products like animal health products, poultry vaccines, poultry diagnostic, laboratory kits and reagents. It markets the veterinary products of many international companies including Ghen Corporation, Japan Maine Biological Laboratories, US Idexx Corporation, US International Diagnostic Systems Corporation, US Biogal Galed Laboratories, Israel and Kemin Europa, Belgium.The companys own production of veterinary vaccines (in Vials) is expected to commence soon. HPL has technical collaborations with Maine Biological Laboratories and Ghen Corporation.During 199697, company successfully implemented veterinary vaccine and commercial production has begun.The company received licenses for producing 10 additional poultry vaccines. It signed a manufacturing agreement with Sinsui Inc for producing poultry vaccines.In 2003, Hester was appointed as the exclusive Indian distributor by BIOPHARM of Czech Republic, for their coccidiosis vaccine LIVACOX.Hester commenced business with Merial in the 3rd quarter of the financial year by importing poultry vaccines from them in 200405 and therefore, name of Company was changed from HESTER PHARMACEUTICALS LIMITED to HESTER BIOSCIENCES LIMITED. The Company embarked on an expansion program, to increase its capacity from 1200 million doses to 4800 million doses, which was commenced in January 2006. The expansion project and the new expanded capacity went onstream in March 2007. The distribution network within India was made functional with company managed depots at Pune, Bangalore, Coimbatore, Hyderabad and Chandigarh, having stateofart cold store facilities to maintain the cold chain. Distribution costs were further cut by embarking on the use of company owned refrigerated vans for deliveries all across India. In January 2010, the company relaunched the freeze dried MD Vaccine after 5 years. A JV was setup in Nepal to facilitate manufacture of specific animal vaccines for international markets in 2011 for a project which costed Rs 15 crores. New technology was acquired. The Company signed a technology transfer agreement with Indian Veterinary Research Institute for acquiring technology to manufacture PPR and Sheep Pox vaccines in 2011. Company relaunched the bivalent Mareks Disease Live vaccine for the poultry, containing HVT SB1 strains in 201213. It operationalised large animal vaccines division in Mar 15. During the financial year 201415, Gujarat Agrofarm Limited became a wholly owned subsidiary of the Company. During financial year 201516, three wholly owned subsidiary Companies namely Gujarat Agrofarm Limited, Diavetra Lifesciences Private Limited and Hester Biosciences (Mauritius) Limited got merged with Company through a Scheme of Arrangement effective on 8 December 2015. Accordingly, the Company allotted and listed its 65 Equity Shares pursuant to Scheme of Arrangement vide order passed by Honble High Court of Gujarat dated 8 December 2015 and the said Shares were listed at NSE Limited and BSE Limited in March, 2016. Leruarua Vetcare (Proprietary) Limited, incorporated in Botswana became an Associate Company with 49% stake of the Company and Innoves Animal Health Private Limited ceases to be an Associate Company due to transfer of shareholding of the Company in FY 201516.The Nepal unit completed trial operations and began commercial manufacturing in November, 2016. Leruarua Vetcare (Proprietary) Limited, Botswana ceases to be an Associate Company due to buyback of entire shareholding by the Associate Company during the FY 201617. The Company held 65% stake in subsidiary Company, Hester Biosciences Nepal Private Limited (HBNPL) and consequently, HBNPL became a subsidiary of Hester Biosciences Limited (Parent Company) during FY 201617.During the year 201718, Company acquired 54.80% in the capital of Texas Laboratories, a firm having a business place at Mehsana Distt. of Gujarat. In June 2017, Texas Laboratories converted into Private Limited Company namely, Texas Lifesciences Private Limited. Further, the Company incorporated 100% whollyowned subsidiary, Hester Biosciences Africa Limited in Tanzania. During the year 201819, Hester Biosciences Limited incorporated 100% whollyowned subsidiary Hester Biosciences Kenya Limited in Kenya.
Read More

Hester Biosciences Ltd FAQs

Hester Biosciences Ltd shares are currently priced at 1417.15 on NSE and 1409.1 on BSE as of 2/29/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of Hester Biosciences Ltd [HESTERBIO] share was -21.54. The Hester Biosciences Ltd [HESTERBIO] share hit a 1-year low of Rs. 1384 and a 1-year high of Rs. 1939.95.

The market cap of Hester Biosciences Ltd is Rs. 1205.55 Cr. as of 2/29/2024 12:00:00 AM.

The PE ratios of Hester Biosciences Ltd is 46.12 as of 2/29/2024 12:00:00 AM.

The PB ratios of Hester Biosciences Ltd is 4.01 as of 2/29/2024 12:00:00 AM

You can easily buy Hester Biosciences Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
or Resume your Application
+91 -

personImage